The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Abstract
Introduction After zidovudine (ZDV), a 3′-azido analogue of thymidine, was found to be an effective antiretroviral drug against HIV [1,2], other nucleoside analogues inhibiting reverse transcriptase (RT) soon followed: didanosine (ddI), zalcitabine (ddC), lamivudine (3TC), stavudine (D4T), and recently abacavir (1592U89) [3–7]. These drugs have demonstrated efficacy in reduction of morbidity and mortality, especially in combination therapy [8–10]. A special feature of some of these drugs is the protection against AIDS dementia complex, which appears to be related to good penetration of the blood–brain barrier [11–13]. Although the introduction of protease inhibitors has changed the management of HIV infection drastically, this cerebro-protective property will assert the role of these nucleoside RT inhibitors (NRTI) as a cornerstone of antiretroviral therapy [9,10]. More than 10 years of experience with NRTI therapy has revealed important adverse effects ranging from mild (myopathy) to fatal in some cases (pancreatitis, liver failure and lactic acidosis). Behind most of these side-effects there appears to be a common mechanism: a decreased mitochondrial energy-generating capacity. In this review we will summarize the literature in which this mechanism is analysed and will emphasize the importance of acquired mitochondrial dysfunction that will accumulate during long-term treatment with antiretroviral nucleoside analogues. Nucleoside analogues and DNA polymerases During the synthesis of DNA, the DNA duplex is unwound by a helicase and each DNA strand directs the synthesis of a complementary DNA strand to generate two DNA duplexes. New nucleotides (triphosphorylated nucleosides: dATP, dCTP, dGTP and dTTP) are added to a pre-existing polynucleotide strand (primer) by an enzymatically catalysed formation of a phosphate ester between the 3′-hydroxyl group of the sugar residue of the nucleotide of the primer and the 5′-phosphate group of the nucleotide to be added. An original DNA strand serves as a template during this process. The enzymes that catalyse this formation of new DNA strands on a template are called DNA polymerases. In eukaryotic cells five types of DNA polymerase are active (DNA polymerase α, β, γ, δ and ε), which all utilize a DNA strand as template. HIV encodes a DNA polymerase (RT) that uses RNA as template. All DNA polymerases have in common the utilization of dNTP as substrate [14–16]. Modification of dNTP can affect the functioning of DNA polymerases: 2′,3′-dideoxy analogues of dNTP (so-called ddNTP) can serve both as inhibitors and substrates of certain DNA polymerases. Since these ddNTP lack the hydroxyl group in the 3′-position, incorporation of a ddNTP will terminate primer elongation (Fig. 1). This mechanism forms the basis of dideoxy sequencing of DNA [17,18] and it was found that ddNTP also inhibited the proliferation of HIV by inhibiting RT [19,20]. All currently used NRTI, such as ZDV, ddC, ddI, 3TC, D4T and abacavir, are dideoxynucleosides, which are phosphorylated intracellularly by host kinases to ddNTP. Since every NRTI (as a ddNTP) might not only inhibit viral RT but also human DNA polymerases, serious toxicity can be expected.Fig. 1: . Scheme of DNA replication. The arrow marks the lacking hydroxyl (OH) group in the 3′-position of a dideoxynucleoside triphosphate (ddNTP), which is responsible for chain termination.For all currently used NRTI, the interaction with human DNA polymerases has been studied (Table 1): in general, DNA polymerase α, δ and ε are insensitive to inhibition by ddNTP, but both DNA polymerases β and γ can be inhibited in vitro by these compounds [15,21–28]. Fortunately, during the cell cycle DNA polymerase α and δ are responsible for the necessary DNA duplication and NRTI apparently do not interfere in this process. DNA polymerases β and ε are involved in DNA repair mechanisms [14] and so far little is known whether the inhibitory effect of NRTI on DNA polymerase β has any pathophysiological importance. However, since DNA polymerase γ is the only DNA polymerase involved in mitochondrial DNA (mtDNA) replication, the inhibitory action of NRTI on this enzyme can easily interfere in mitochondrial replication and function [16,24,28–30]. Interestingly, as an exception to the other NRTI, 3TC is both an inhibitor of the polymerase activity and a substrate of the integral 3′–5′ exonuclease activity of DNA polymerase γ, which makes incorporation less feasible.Table 1: . Kinetic interactions of reverse transcriptase inhibitors with human DNA polymerases.Other RT inhibitors (RTI) are also used as HIV inhibitors, including non-nucleoside analogues such as nevirapine, delavirdine, efavirenz [31–33], and nucleotide analogues such as adefovir [9-(2-phosphomethoxyethyl)adenine (PMEA)] [23,34]. Although data on the affinity for human DNA polymerases are less abundant for these compounds, it appears that nonnucleoside analogues do not interfere with any of these polymerases, whe
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Mitsuya, H., Weinhold, K. J., Furman, P. A., St Clair, M. H., Lehrman, S. N., Gallo, R. C., Bolognesi, D., Barry, D. W., & Broder, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.20.7096 · Cited by 1,866
Diseases of the mitochondrial DNA
Wallace, D. C. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.005523 · Cited by 1,319
Mitochondrial Genetics: A Paradigm for Aging and Degenerative Diseases?
Wallace, D. C. (1992) · Science · doi:10.1126/science.1533953 · Cited by 1,262
Mitsuya, H., & Broder, S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1911 · Cited by 1,039
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., et al. (1998) · JAMA · doi:10.1001/jama.280.1.78 · Cited by 995
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 844
Yarchoan, R., Weinhold, K., Lyerly, H. K., Gelmann, E., Blum, R., Shearer, G., Mitsuya, H., Collins, J., Myers, C., Klecker, R., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92808-4 · Cited by 802
Mitochondrial toxicity of antiviral drugs
Lewis, W., & Dalakas, M. C. (1995) · Nature Medicine · doi:10.1038/nm0595-417 · Cited by 770
Carpenter, C. C. J. (1997) · JAMA · doi:10.1001/jama.1997.03540480062040 · Cited by 725
Cited by
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Brinkman, K., Smeitink, J. A., Romijn, J. A., & Reiss, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06102-4 · Cited by 866
Self-citationAberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Carr, A., Miller, J., Law, M., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200002180-00001 · Cited by 630
Metadata
- Authors
- Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P.
- Venue
- AIDS
- Published
- 1998-10
- Volume
- 12
- Issue
- 14
- Pages
- 1735-1744
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2041841997
- Cited by
- 847
- References
- 77
- FWCI
- 37.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. https://app.cochat.ai/papers/10.1097/00002030-199814000-00004
- The paper
- Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. https://doi.org/10.1097/00002030-199814000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.